Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants

Conflicting data suggest that statins could cause chronic liver disease in certain group of patients, while improving prognosis in those with chronic viral hepatitis (CVH). To quantify the potential protective role of statins on some main liver-related health outcomes in clinical studies on CVH pati...

Full description

Saved in:
Bibliographic Details
Published in:Annals of medicine (Helsinki) 2021-01, Vol.53 (1), p.1228-1243
Main Authors: Vahedian-Azimi, Amir, Shojaie, Sajad, Banach, Maciej, Heidari, Farshad, Cicero, Arrigo F. G., Khoshfetrat, Masoum, Jamialahmadi, Tannaz, Sahebkar, Amirhossein
Format: Article
Language:English
Subjects:
Cardiology & Cardiovascular Disorders
Chronic Disease
Disease Progression
fibrosis
hepatitis
Hepatitis, Viral, Human - drug therapy
Hepatitis, Viral, Human - epidemiology
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
liver
Liver Cirrhosis - prevention & control
Liver Failure - prevention & control
Liver Neoplasms - prevention & control
prognosis
Review
Statins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Conflicting data suggest that statins could cause chronic liver disease in certain group of patients, while improving prognosis in those with chronic viral hepatitis (CVH). To quantify the potential protective role of statins on some main liver-related health outcomes in clinical studies on CVH patients. Data Sources: The search strategy was explored by a medical librarian using bibliographic databases, from January 2015 to April 2020. Data synthesis: The results showed no significant difference in the risk of mortality between statin users and non-users in the overall analysis. However, the risk of mortality significantly reduced by 39% in statin users who were followed for more than three years. Moreover, the risk of HCC, fibrosis, and cirrhosis in those on statins decreased by 53%, 45% and 41%, respectively. Although ALT and AST reduced slightly following statin therapy, this reduction was not statistically significant. A significant heterogeneity among studies was observed, resulting from differences in clinical characteristics between statin users and non-users, study designs, population samples, diseases stage, comorbidities, and confounding covariates. Not only long-term treatment with statins seems to be safe in patients affected by hepatitis, but also it significantly improves their prognosis.
ISSN:0785-3890
1365-2060
DOI:10.1080/07853890.2021.1956686